Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes

被引:35
作者
Kasprzycka, M
Majewski, M
Wang, ZJ
Ptasznik, A
Wysocka, M
Zhang, Q
Marzec, M
Gimotty, P
Crompton, MR
Wasik, MA
机构
[1] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[5] Warsaw Med Univ, Dept Clin Immunol, Warsaw, Poland
[6] Inst Hematol & Blood Transfus, Dept Hematol, Warsaw, Poland
[7] Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Surrey, England
关键词
D O I
10.2353/ajpath.2006.050521
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tyrosine kinases play a fundamental role in cell proliferation, survival, adhesion, and motility and have also been shown to mediate malignant cell transformation. Here we describe constitutive expression of the protein tyrosine kinase Brk in a large proportion of cutaneous T-cell lymphomas and other transformed T- and B-cell populations. The kinase is expressed in the nuclear localization and activated state. Brk expression was also induced in normal T cells on their activation. Introduced expression of the Brk gene resulted in markedly diminished cytokine and growth factor dependence of transfected BaF3 lymphocytes in regard to their in vitro proliferation and survival. Brk also conferred in vivo oncogenicity on the BaF3 cells. siRNA-mediated inhibition of the endogenous Brk in malignant T cells diminished their growth and survival capacity. These findings document inducible expression of Brk in normal T lymphocytes and persistent expression of the activated kinase in malignant T and B cells. Furthermore, our results indicate that Brk may play a key role in lymphomagenesis, hence identifying the kinase as a potential therapeutic target in lymphomas.
引用
收藏
页码:1631 / 1641
页数:11
相关论文
共 30 条
[1]   BRK tyrosine kinase expression in a high proportion of human breast carcinomas [J].
Barker, KT ;
Jackson, LE ;
Crompton, MR .
ONCOGENE, 1997, 15 (07) :799-805
[2]   Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas [J].
Born, M ;
Quintanilla-Fend, L ;
Braselmann, H ;
Reich, U ;
Richter, M ;
Hutzler, P ;
Aubele, M .
JOURNAL OF PATHOLOGY, 2005, 205 (05) :592-596
[3]   Brk activates Rac1 and promotes cell migration and invasion by phosphorylating paxillin [J].
Chen, HY ;
Shen, CH ;
Tsai, YT ;
Lin, FC ;
Huang, YP ;
Chen, RH .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (24) :10558-10572
[4]   Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability [J].
Derry, JJ ;
Richard, S ;
Carvajal, HV ;
Ye, X ;
Vasioukhin, V ;
Cochrane, AW ;
Chen, TP ;
Tyner, AL .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (16) :6114-6126
[5]   Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells [J].
Derry, JJ ;
Prins, GS ;
Ray, V ;
Tyner, AL .
ONCOGENE, 2003, 22 (27) :4212-4220
[6]  
Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO
[7]  
2-F
[8]   The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis [J].
Haegebarth, A ;
Nunez, R ;
Tyner, AL .
CELL CYCLE, 2005, 4 (09) :1239-1246
[9]   The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2 [J].
Haegebarth, A ;
Heap, D ;
Bie, WJ ;
Derry, JJ ;
Richard, SP ;
Tyner, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (52) :54398-54404
[10]   Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation [J].
Harvey, AJ ;
Crompton, MR .
ONCOGENE, 2003, 22 (32) :5006-5010